Vest Financial LLC Has $1.20 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Vest Financial LLC increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 73.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,252 shares of the biopharmaceutical company's stock after acquiring an additional 20,018 shares during the quarter. Vest Financial LLC's holdings in Pfizer were worth $1,197,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Tallon Kerry Patrick acquired a new stake in Pfizer during the 4th quarter worth $509,000. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. Silver Oak Securities Incorporated increased its holdings in Pfizer by 13.7% in the fourth quarter. Silver Oak Securities Incorporated now owns 15,886 shares of the biopharmaceutical company's stock valued at $420,000 after purchasing an additional 1,919 shares during the last quarter. Finally, Leo Wealth LLC lifted its stake in Pfizer by 48.8% in the fourth quarter. Leo Wealth LLC now owns 35,767 shares of the biopharmaceutical company's stock valued at $949,000 after buying an additional 11,722 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

PFE opened at $23.36 on Friday. The company has a market capitalization of $132.81 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57. The business's 50-day moving average price is $22.95 and its two-hundred day moving average price is $25.00. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm earned $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.36%. Pfizer's payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group boosted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.